What were the results of the Harmony Outcomes study?
The Harmony Outcomes study found that albiglutide can reduce the risk of major adverse cardiovascular events, such as death from cardiovascular causes, non-fatal heart attack or stroke, and hospitalization for unstable angina, in patients with type 2 diabetes and cardiovascular disease.